Quality and complications after cataract surgery by Rønbeck, Margrethe
 Institutionen för klinisk neurovetenskap 
Quality and complications after cataract 
surgery 
  
AKADEMISK AVHANDLING 
som för avläggande av medicine doktorsexamen vid Karolinska 
Institutet offentligen försvaras i aulan, S:t Eriks Ögonsjukhus  
Fredagen den 14 mars, 2014, kl 09.00 
av 
Margrethe Rønbeck  
 
Huvudhandledare:  
Docent Maria Kugelberg  
Karolinska Institutet 
Institutionen för klinisk neurovetenskap 
 
Bihandledare:  
Medicine Doktor Annemari Koivula  
Karolinska Institutet 
Institutionen för klinisk neurovetenskap 
 
 
Docent Ulla Kugelberg  
Karolinska Institutet 
Institutionen för klinisk neurovetenskap 
 
Fakultetsopponent: 
Medicine Doktor Björn Johansson  
Linköpings Universitet 
Institutionen för klinisk och experimentell 
medicin  
 
Betygsnämnd: 
Docent Eva Mönestam  
Umeå Universitet  
Institutionen för Klinisk Vetenskap 
 
Professor Liv Drolsum  
Universitetet i Oslo  
Institutt for klinisk medisin 
 
Docent Enping Chen  
Karolinska Institutet 
Institutionen för klinisk neurovetenskap 
 
Stockholm 2014 

 ST. ERIK EYE HOSPITAL 
Department of clinical neuroscience,  
Karolinska Institutet, Stockholm, Sweden 
 
QUALITY AND 
COMPLICATIONS AFTER 
CATARACT SURGERY 
Margrethe Rønbeck  
 
 
Stockholm 2014 
2014
Gårdsvägen 4, 169 70 Solna
Printed by
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All previously published papers were reproduced with permission from the publisher. 
 
Published by Karolinska Institutet. Printed by [name of printer] 
 
© Margrethe Rønbeck, 2014 
ISBN 978-91-7549-467-8 
  

 ABSTRACT 
Research about IOL parameters` influence on posterior capsule opacification (PCO) 
and lens glistenings may be rapidly applied in clinical practice and may help the 
industry to manufacture intraocular lenses (IOLs) with higher quality, which will be 
of benefit to the patients.  
In paper I we compared the influence on PCO of 3 different IOLs; a sharp-edged 
hydrophobic acrylic, a round-edged silicone and a round-edged heparin-surface-
modified polymethylmethacrylate (HSM-PMMA) IOL in a 5 year randomized 
prospective study with 180 patients. The PCO fraction and severity did not differ 
significantly between the hydrophobic acrylic and the silicone IOL 5 years after 
surgery. The capsulotomy rate was significantly higher in the silicone (29%) than in 
the acrylic IOL group (8%). The HSM-PMMA IOL had significantly higher PCO 
fraction and severity and capsulotomy rate (54 %) than the arylic and the silicone 
IOLs. 
In paper 2 PCO and anterior capsule opacification (ACO) were assessed 12 years 
after surgery in the same patients as in paper I. The PCO fraction and severity did not 
differ between the hydrophobic acrylic and the silicone IOL 12 years after surgery. 
The PCO fraction was significantly higher in the HSM-PMMA IOL than in the 
silicone IOL, but not higher than in the acrylic IOL. The PCO severity did not differ 
between the HSM-PMMA and the hydrophobic acrylic and the silicone IOLs. There 
was no significant difference in overall survival without capsulotomy between the 
acrylic and the silicone or the silicone and the HSM-PMMA IOLs. The acrylic had 
significantly better overall capsulotomy free survival than the HSM- PMMA IOL. 
The median capsulotomy free survival time was higher in the silicone IOL (>150 
months) than the acrylic (108 months) and the HSM-PMMA (53 months) IOLs. 
 
In paper III we compared lens glistenings in the same 3 IOLs as in paper I in 46 
eyes; and investigated the influence of dioptric power on lens glistenings 12 years 
after cataract surgery. There was significantly more glistenings in the hydrophobic 
acrylic than in the silicone and the HSM-PMMA IOL, and significantly more 
glistenings in the silicone than in the HSM-PMMA IOL. The IOL dioptric power did 
not influence the amount of lens glistenings in the acrylic IOL. The other two IOLs 
had too little glistenings to be evaluated for this purpose. 
  
In paper IV we studied factors influencing patient-reported visual function after 
cataract surgery in 14 817 patients, using data from the Swedish National Cataract 
Register. We found that the improvement in subjective visual function, the 
postoperative visual function and the satisfaction with vision were influenced by age, 
preoperative and postoperative corrected visual acuity, ocular comorbidity, a first- or 
second-eye surgery, gender, and achieved postoperative refraction.  
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LIST OF ABBREVIATIONS 
  
AQUA Automated Quantification of After-Cataract 
ACO Anterior capsule opacification 
°C Celsius degrees 
CCT Classical test theory 
CDVA Corrected distance visual acuity 
ECCE Extracapsular cataract extraction 
EPCO Evaluation of Posterior Capsular Opacification  
EU European Union 
FDA Food and drug administration 
HSM Heparin surface modified 
IOL Intraocular lens                                                       
LEC Lens epithelial cell 
logMAR Logarithm of the minimum angle of resolution 
MICS Micro incision cataract surgery 
NCR National cataract register 
Nd:YAG Neodymium:Yttrium Aluminium Garnet  
NIKE Nationell Indikationsmodell för kataraktextraktion 
OR Odds ratio 
PCO Posterior capsule opacification 
PMMA Polymethyl methacrylate 
POCO Posterior capsule opacification software 
USA United Stated of America 
VA Visual acuity 
VF-14 Visual Function Index 14 
Tg Glass transition temperature                                           
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1 POSTERIOR CAPSULE OPACIFICATION 
 
1.1  INTRODUCTION 
 
In modern phacoemulsification surgery with intraocular lens (IOL) implantation, the 
lens contents are removed leaving the posterior lens capsule intact. The IOL is 
implanted into the remaining capsular bag. The posterior capsule forms an anatomical 
barrier between the anterior and posterior segments of the eye, reducing the risk of 
posterior segment complications following surgery.  To achieve good visual function 
after surgery, the posterior capsule should be clear. The posterior part of the capsular 
bag, i.e. the posterior capsule, can be opacified months to years after surgery, i.e. 
posterior capsule opacification (PCO) (Figure 1).   
 
Figure 1. Posterior capsule opacification. 
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1.2  IMPLICATIONS OF PCO 
 
There has been a substantial amount of research over the years to find safe and 
effective methods to reduce the amount of PCO, both in the short and long time run. 
The many implications of PCO, both clinical and financial, give investigators many 
reasons to continue this research. 
PCO has been recognized since the origin of extra capsular cataract 
surgery (ECCE).  Sir Harold Ridley noted PCO in his first IOL implantations in the 
1950s. The incidence of PCO in the 1980s and early 1990s ranged between 25-50 %. 
[1, 2] Since then, considerable improvements in IOL design and surgical techniques 
have taken place, which has led to a reduction in PCO incidence to less than 10 % in 
some studies.[1, 2] Despite this, PCO remains the most common complication after 
cataract surgery.  
It still is a major clinical problem, especially in pediatric cataract 
surgery, where the incidence is very high (>40%; sometimes 100%). Delayed 
diagnosis of PCO in children may lead to irreversible amblyopia.[3] 
PCO leads to loss of visual acuity and contrast vision.[4, 5] The 
mechanism behind the vision loss is forward light scattering into the eye by the PCO 
or movement and decentration of the IOL. The observed amount of PCO does not 
always correlate to visual symptoms. Some patients may have significant symptoms 
with only mild haze in the posterior capsule while others are relatively asymptomatic 
with significant PCO on slit lamp examination.[6] The currently only available 
treatment for adults is Nd:YAG laser capsulotomy, which clears the visual axis by 
creating a central opening in the opacified posterior capsule. This treatment has many 
significant complications including transient intraocular pressure rise,[7, 8] laser IOL 
cracks, IOL dislocation, cystoid macular edema,[8] retinal detachment[9] or floaters 
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due to remaining posterior capsule pieces; it often does not improve visualization of 
the peripheral retina.[10] In highly myopic eyes it is especially important to avoid 
PCO, because a Nd: YAG capsulotomy will induce a greater risk for retinal breaks 
and retinal detachment.[11] It also leads to a major cost burden on the health care 
systems. In the USA Nd:YAG laser treatments of almost one million PCO patients 
per year cost up to $250 million annually around the millennium.[12] The YAG laser 
treatment is often not available in developing countries. Also in western countries, old 
patients may contribute further vision loss after cataract surgery to “old age”, and will 
be delayed in seeking treatment.[13] Patients implanted with premium lenses are 
more vulnerable to PCO. In multifocal IOLs even small amounts of PCO may cause a 
substantial clinical impact.[14] Also, bag fibrosis is one of the reasons behind the 
difficulties producing a really accommodative IOL.  These IOLs often rely on a 
dynamic process of presumed active accommodation, a mechanism that could be 
prevented by bag fibrosis or an Nd: YAG capsulotomy.  
 
1.3 PATHOPHYSIOLOGY 
 
The lens epithelial cells (LECs) in the normal crystalline lens are restricted to the 
region under the anterior lens capsule and to the equatorial lens bow. They consist of 
a single row of cuboidal cells, and can be divided into two different biological zones, 
each zone being the primary source of one of the two PCO types; fibrotic or 
regenerative. 
The first biological zone is the LECs residing in the zone of the anterior 
lens capsule (A cells). They consist of a monolayer of flat cuboidal, epithelial cells 
with very low mitotic activity. After cataract surgery the anterior epithelial cells may 
proliferate and transdifferentiate into myofibroblast, which lay down collagen 
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(fibrous metaplasia). The anterior LECs are the major source of anterior capsule 
opacification (ACO)/fibrosis. ACO may hinder visualization of the peripheral retina 
and can cause decentration and tilting of the IOL. In the more extreme cases, they 
also may cause capsular phimosis (shrinking of the anterior capulorhexis).[15] They 
also may migrate posteriorly and cause wrinkles and fibrosis of the posterior capsule, 
i.e. fibrotic PCO.  
The second biological zone is the LECs residing in the equator region 
(E cells). Cell mitosis, division and proliferation are quite active in this region. The 
LECs in this zone are important in the formation of regenerative PCO. After surgery 
with IOL implantation the residual equatorial LECs try to produce new lens fibers to 
build up a new lens. This process is called lens fiber regeneration. The E-cells tend to 
form large balloon like bladder cells (Wedl cells). Clinically regenerative PCO is 
visible as pearls (Elschnig pearls). The morphology of Elschnig pearls has been 
shown to change within time intervals of only 24 hours. This dynamic behavior of 
PCO is illustrated by the appearance and disappearance of pearls as well as 
progression and regression of pearls within this short time intervals.[16]  
Equatorial cells (E-cells) also form Soemmering's ring, using cortical remnants as a 
substrate. The Soemmering's ring, which is a donut shaped lesion surrounding the 
IOL optic in the peripehery of the capsular bag, is a direct precursor to regenerative 
(pearl) PCO. The equatorial LEC can also contribute to the fibrous form of 
opacification, but the most likely type of growth is in the direction of regenerative 
PCO.  Regenerative PCO is much more common than fibrotic PCO, and is the main 
cause of a decrease in visual function after cataract surgery.  
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1.4  FACTORS INFLUENCING  PCO 
 
Factors influencing PCO may be patient, surgery or IOL related. The patient factor 
age influences PCO the most,[3, 17] but also concomitant intraocular or systemic 
disease may contribute.[18] The influence of diabetes mellitus on PCO is still 
controversial. [19] [20, 21]  
In the last decades surgical techniques and IOL design in cataract 
surgery were improved, which has resulted in reduced incidence of PCO. The 
evolution of cataract surgery techniques and IOL design is a good example of the 
improvement of medicine with the active cooperation of science and industry. The 
reciprocal evolution of cataract surgery techniques, IOL implantation and the 
management of PCO have gone hand in hand.  
The main surgery related factors in phacoemulsification that reduce 
PCO include hydrodissection-enhanced cortical cleanup, in-the-bag (capsular) 
fixation of the IOL[22] and position of the anterior capsulorhexis. With 
hydrodissection-enhanced cortical cleanup the capsule is efficiently separated from 
the cortex by a flow of fluid. This facilitates cortical and cellular cleanup in the 
capsular bag. With in-the-bag (capsular) fixation of the IOL the optic stays fully in 
the bag and is in direct contact with the posterior capsule and the IOL optic barrier 
effect is maximized. If one or both haptics are not placed in the bag, cells may grow 
posteriorly toward the visual axis in a potential created space.[22]  The anterior 
capsulorhexis should be completely centered on the optic, i.e. the capsulorhexis 
should be in complete contact with the IOL optic 360 degrees around to induce less 
PCO development.[23, 24] A capsulorhexis that is partly on and off the IOL optic 
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leads to capsular bag shrinkage exerting an asymmetrical force down on the IOL, 
causing the IOL to tilt away from the posterior capsule. The LECs tend to penetrate 
under the IOL where the capsulorhexis is off the IOL surface.[24 A capsulorhexis 
completely centered on the IOL optics is easier to achieve surgically when the optic is 
larger.  
IOL design has improved considerably the last decades, and this has 
further contributed to the reduction in PCO. The AcrySof IOL was introduced by 
Alcon Laboratories in 1993, and in the early clinical trials the German surgeon 
Echkard Medhorn observed that this IOL had remarkable clear posterior capsules.[13] 
Originally researchers misattributed the PCO preventing property of the AcrySof 
IOLs to be caused by the hydrophobic acrylic material. In the late nineties animal 
studies by Nishi et al showed that PCO inhibition may be dependent on IOL design, 
i.e. the sharp edge, and not material.[25, 26] Later on several clinical studies also 
showed that it was the sharp posterior edge and not the hydrophobic acrylic material 
that was causing less PCO. Currently the main IOL related factor known to reduce 
PCO development is a sharp optic edge.[27-29] 
The advantage of the posterior edge is mainly showed in studies of 1-3 
years, and is only shown after 5 years in the silicone IOL.[29]  The sharp-edged 
design creates a bending of the posterior capsule, and the fibrosis occurring in the bag 
after IOL implantation causes the posterior capsule to be pulled against the anterior 
capsule in in a shrink-wrap fashion, leading to the fusing-together of the anterior and 
posterior capsules. [30] The IOL and the sharp edge are thereby pushed against the 
posterior capsule creating a mechanical barrier against proliferating lens epithelial 
cells (LECs) behind the IOL. One study created a mathematical model of the forces 
between an IOL and the capsule.[31]  
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Even though the sharp posterior edge is considered the most important 
PCO inhibiting factor, it is still not clear weather different optic materials also may 
offer advantages over one another in terms of PCO inhibition. In the publications of a 
series of histological and immune histochemical studies of explanted IOLs, Linnola et 
al launched the “Linnola sandwich theory” in year 2000 as an explanation of why the 
hydrophobic acrylic IOLs may have less PCO than the PMMA and silicone IOLs. 
This theory suggests that the bio adhesive forces between the hydrophobic acrylic 
IOL material and the capsular bag are stronger than between other IOL materials and 
the capsular bag. They suggested that fibronectin is the major extracellular protein 
responsible for this stronger attachment, because of its stronger binding to the 
hydrophobic acrylic material than to other IOL materials.[32, 33]  
Several clinical studies with duration of 1-3 years studies have shown 
that hydrophobic acrylic IOLs were associated with less PCO than silicone IOLs, but 
most of these studies compared acrylic IOLs with sharp edges to silicone IOLs with 
round edges.[34, 35] Other clinical studies have shown non-significant trends of 
silicon IOLs having less PCO than hydrophobic acrylic IOLs.[36] [37] 
There was no significant differences in PCO prevention between 
different IOL optic materials (hydrophobic acrylic, hydrophilic acrylic, PMMA, 
silicone) in a meta-analysis (Cochrane review), although the silicone material induced 
less PCO in several studies.[38] Several of the studies in the meta-analysis compared 
acrylic IOLs with sharp edges with silicone IOLs with round edges, which 
complicates the data. 
Some studies have shown less PCO development with the hydrophobic 
acrylic material than with the hydrophilic acrylic material.[39] This is explained by 
the quality and sharpness of the sharp edge profile rather than the material. 
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Hydrophobic acrylic and silicone IOLs have in electron microscopy studies been 
shown to have sharper posterior optic square edge than most hydrophilic acrylic 
IOLs.[40] This is likely because of the posterior edge profile of hydrophilic materials 
are damaged in the manufacturing process in which they are lathe cut in a dehydrated 
state, then rehydrated and then dried and polished to remove processing burr. 
Different hydrophobic acrylic IOLs also differ in edge profiles, and the sharper the 
edge, the better the PCO prevention.[41] The limit the material puts on the 
manufacturing process seems to determine the sharpness of the edge profile. 
However, currently Bausch&Lomb launches a hydrophilic micro incision IOL 
(INCISE), which they claim have one of the sharpest edges on the market. 
To inhibit PCO the best, the optic edge should be sharp 360 degrees 
around and not interrupted in the optic-haptic junction. An interrupted sharp edge in 
the optic-haptic junctions will lead to centripetal LEC migration behind the IOL optic 
in the area of the junction.[42]  
Posterior convex and biconvex IOLs have been shown to induce less 
PCO. [43] Retro angulation of the IOL haptics or anterior capsule fibrosis (ACO) can 
potentially increase the retropulsive effect of the pressure barrier created by the sharp 
edge.[13] Increasing hydrophobicity of the IOL material (eg, silicone>hydrophobic 
acrylic> PMMA>hydrophilic materials) seems to increase the amount of ACO. More 
ACO may increase the retropulsive force pushing the IOL against the posterior 
capsule, resulting in better PCO prevention. The drawback is that ACO may hinder 
visualization of the peripheral retina and can cause decentration and tilting of the 
IOL. 
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 1.5  METHODS USED TO ASSESS PCO 
 
Several retroillumination image analysis systems have in the last decades been used 
to quantify PCO, and they are known by various acronyms such as the semiobjective 
system POCOman, the subjective system EPCO and the objective systems POCO and 
AQUA. They have been used in a vast number of studies and have relative 
advantages and disadvantages.[44] [45, 46] Scheimpflug images have also been used 
to assess PCO.[47]  
In addition Nd: YAG capsulotomy rates have been used for many years 
to assess the amount of PCO development.  
 
1.6 PCO IN THE LONG TIME RUN 
 
The follow-up times for most PCO studies are 1- 3 years. Only a few studies have 
follow-up times of 5 year or more. Many patients will live more than 5 years after 
cataract surgery. The average life expectancy has increased by 10 years during the 
last 50 years in the European Union (EU) countries, Japan, and the USA. In the EU 
the expected lifespan for men is about 76 years and for women 82 years.[48]. The life 
expectancy at age 65 years in the EU, i.e., the mean number of years still to be lived 
by a man or a woman who has reached age 65, is about 21 years for women and 17 
years for men. The life expectancy in Sweden has increased by 2 years for men and  
1.5 years for women in the last 10 years. In 2010, the life expectancies for women 
and men were 83.5 and 79.5 years, respectively.[49] Of the cataract surgeries reported 
to the Swedish National Cataract register in 2010, 29% of the operated patients were 
younger than 70 years. The average age of Swedish patients undergoing 
phacoemulsification was 74.2 years in 2010.[50] 
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In addition, refractive lens exchange is performed in patients much younger, and IOL 
implantation also is performed in children. This indicates that many patients will live 
more than 10 years after phacoemulsification surgery, and that sustained PCO 
inhibition over time is important. Evaluation of PCO development over the long term 
after surgery is therefore of high interest. 
The few PCO studies with duration of 5 years or more have reported 
reduced PCO preventing effect of the sharp posterior edge in the long time run, which 
emphasize the need for longtime studies of PCO.[51, 52] 
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2 LENS GLISTENINGS 
 
2.1 DEFINITION 
 
Glistenings are fluid-filled micro vacuoles that form within the matrix of the 
intraocular lens (IOL) when immersed in an aqueous environment. The hydrophobic 
acrylic IOL is the IOL that has received most of the attention in association with lens 
glistenings in the literature. Only a few studies have described the phenomenon in 
other IOL materials. Although the hydrophobic acrylic IOL has the greater degree of 
glistenings, this phenomenon have been observed in all IOL materials, including 
hydrophilic acrylic, silicone and PPMA materials. [53-55]  
There has been some confusion in the literature around the terms lens 
glistening and surface light scattering. Both phenomena depend upon water phase 
separation and the formation of micro vacuoles containing water in the optic, 
although the sizes of the vacuoles is much smaller with surface light scattering than 
with glistenings.[56-60]  The trace water molecules forming in the subsurface region 
causing surface scattering is not clinically seen as micro vacuoles.  Glistenings 
observed clinically are mostly up to 10 μm in diameter, and larger glistenings up to 
20 μm may be seen when using temperature fluctuations in in vitro studies.[61, 62] 
The glistenings have been shown to be distributed throughout the entire lens.[63] 
However, glistenings, represented by light scattering in Scheimpflug images,  have 
been found to be most prominent near the anterior and posterior IOL surfaces.[64] 
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2.2 METHODS USED TO ASSESS GLISTENINGS 
 
Common methods used to assess glistenings are subjective/semiquantitative grading 
of glistening density in the slit lamp,[53, 63] slit lamp photography of the IOL at high 
magnification with manual grading of the size and number of glistenings[55] and 
digital image analysis.[65] Scheimpflug photography is also used to quantify 
glistenings, and this method was first suggested by Klos.[66] With the Scheimpflug 
method light scattering both inside the optic and at the surface, can be used to assess 
the degree of glistenings (Figure 2).[67]  
Figure 2. Scheimpflug images showing no glistenings in the superior image (the optic 
is hardly visible), compared to glistenings at the anterior and posterior IOL surface in 
the inferior image. 
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The light scattering is measured as computer compatible tape (CCT). This is a 
measure of reflected light from 0 (black) to 255 (white). Behndig and Mönestam 
evaluated the Scheimpflug method in a 10 year study and found a strong correlation 
between postoperative time and light scattering, interpreted as glistenings. The 
authors found a higher density of glistenings near the surfaces, with the anterior 
surface having the highest degree of glistenings.[64] In a letter to the editor Mackool 
and Colin[68] expressed their doubt in using the Scheimpflug method to quantify 
glistenings. In their opinion the Scheimpflug technique could not differentiate 
between light scattering due to glistenings and light scattering due to other 
parameters, such as biological biomaterials, PCO or aqueous-optic interface. Another 
study refuted this theory.[69] 
 
2.3 MECHANISM OF FORMATION 
 
Polymers with various architectural structures are used in the manufacturing of IOLs. 
Micro voids can be found within the network of the polymers. When immersed in an 
aqueous environment for an extended time, the polymers generally absorb water. The 
amount of water absorbed in relation to IOL weight (water absorption rate) varies in 
different IOL materials. The currently available hydrophobic IOLs generally have a 
water absorption rate of less than 1 %.[70] The water is present in the form of vapor 
within the polymer network and is therefore not visible. However, a visible water 
drop may form if water vapor detaches from its surrounding matter and gathers into a 
void within the polymer. The micro vacuoles have a sparkling appearance because 
there is a significant difference between the refractive index of water and the IOL 
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polymer (eg. 1.555 for AcrySof IOLs), leading to refraction of light at the water-
polymer interfaces. The term glistening is therefore suitable. 
The water absorption rate of IOL polymers changes with various 
temperature.[70] The glass transition temperature (Tg) marks the transition 
temperature from where the polymer exhibits rigid properties (lower temperatures) to 
where it is flexible (higher temperatures). When the temperature is below the glass 
transition temperature, water absorption is minimal for hydrophobic acrylic IOLs. 
However, water absorption increases when the polymer start to soften at temperatures 
above Tg. The currently used hydrophobic acrylic polymers normally have Tgs close 
to room temperature. 
If the IOL is placed in warm water, the polymer becomes oversaturated. 
The excess of water gathers inside the voids within the polymer network. If the 
temperature is then lowered, the water will be visible as glistenings because of phase- 
separation. It is likely that small fluctuations in temperature in aqueous humor may 
lead to IOL glistenings in vivo. [57] Glistening formation is not observed when the 
IOL is placed in water below the Tg of the IOL material, e.g. at 15 degrees C, as 
shown in Japanese studies.[58] 
The U.S. Food and Drug Administration (FDA) has recently suggested a 
different mechanism for glistening formation.[71] They propose that hydrophilic 
impurities are generated during polymerization in the manufacturing process of IOLs. 
The impurities are believed to segregate into polymer voids, leading to an osmotic 
pressure difference between the cavity and the aqueous humor.  The influx of water 
into the cavity is thought to deform the surrounding polymer until it cracks or tears. 
This process would continue until equilibrium is achieved. 
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2.4 FACTORS INFLUENCING GLISTENING FORMATION 
 
Several factors, such as IOL optic material, manufacturing technique, IOL 
packaging,[72] IOL dioptric power, [73] changes in temperature,[57] glaucoma, [74] 
breakdown of the blood–aqueous barrier,[75]  and the use of anti-inﬂammatory eye 
drops containing a surfactant[67, 76] and antiglaucoma eye drops [74, 77] may 
influence glistening formation. Some studies indicate that the IOL dioptric power 
influence the glistening formation,[78] while others have not found any 
association.[79]   
Hydrophobic acrylic IOLs are manufactured with 2 different processes: 
cast molding and lathe cutting. In the cast-molding process a monomeric mixture is 
polymerized in a casting mold and thereafter detached from the mold. This method is 
suitable for large-scale production. The disadvantage may be heterogeneous parts 
containing unreacted monomers. In the lathe cutting process a monomeric mixture is 
polymerized into acrylic sheets, and subsequently each IOL is lathe-cut for polishing 
to remove heterogeneous parts. This process may have a higher cost because of more 
processing steps. Studies have shown significantly more glistening with the cast 
molding process.[80]  
The first reports of glistenings in the AcrySof IOLs were related to IOLs 
packaged in the AcryPak system, which was not used in the clinical trials before FDA 
approval. The AcryPac, which contained both the IOL and a folder, underwent 
terminal sterilization within this plastic case. Some authors believed the terminal 
sterilization facilitated lens glistening by changing the microenvironment.[72] The 
AcryPak was voluntarily withdrawn by Alcon.  
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Studies show that glistening also occur with the currently Wagon 
Wheel–packaged AcrySof IOLs, even though the earlier used AcryPac- packaged 
IOLs demonstrated significantly more glistening formation.[72] The core studies of 
this IOL used the Wagon Wheel- packaged IOLs. 
 
2.5 INFLUENCE ON VISUAL FUNCTION 
 
There is still not an agreement in the literature weather lens glistening influence 
visual function or not. 
Several studies reported that the presence of glistenings does not affect 
visual function. One study found no correlation between lens glistenings and visual 
acuity, glare testing, wavefront analysis or contrast sensitivity, except there was a 
borderline correlation with contrast sensitivity in the high spatial resolution patch.[65] 
Another intrapatient study compared the same acrylic (AcrySof MA60BM) and 
silicone [SI40NB; Abbott Medical Optics (previously Allergan)] IOLs as in our 
study. Despite the finding of glistenings in 40% of the acrylic IOL, there was no 
significant difference in visual function between the 2 IOLs.[81] Hayashi et al found 
that visual function and optical aberrations were not significantly different for eyes 
implanted with a hydrophobic acrylic IOL compared with eyes implanted with 
silicone or PMMA IOLs more than 10 years after implantation, even though there 
was significantly more glistenings with the acrylic IOL.[82] Colin et al reported no 
statistically significant difference in VA, glare disability, and contrast sensitivity 
between groups with or without glistenings.[83]  
Some clinical studies have reported an influence on visual function by 
lens glistenings. One study evaluated glistenings effect on visual function in 42 eyes 
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implanted with Wagon-Wheel packed AcrySof IOL 2.4 years postoperatively, and 
found significantly more glistenings in IOLs with 2+ or greater glistenings compared 
with IOLs with less than 2+ glistenings. There was no statistically significant 
difference in glare testing and contrast sensitivity between the same groups in this 
study.[81] Another study found that a higher degree of glistenings decreased contrast 
sensitivity.[63] One study found that glistenings influenced contrast sensitivity at the 
higher spatial frequency. However, there appear to be some discontinuities in this 
study, as earlier criticized.[70]  
 
2.6 PROGRESSION OVER TIME 
 
There is a controversy in the literature wether lens glistenings continue to increase 
over time or stabilize and stop developing after a period of initial increase.  
A recent retrospective study  with 260 eyes implanted with AcrySof 
reported no significant difference regarding glistenings incidence and severity in eyes 
with a follow-up shorter than 24 months compared to eyes with a longer follow-
up.[74] Miyata et al. followed 129 eyes with AcrySof IOLs for 20 months in a 
prospective clinical study.[61] The glistenings became stable a few months after they 
first appeared. This was in concordance with an experimental study performed by the 
same authors, in which they immersed the IOLs in solution and decreased the 
temperature from 50°C to 35°C. No further changes in glistening formation was seen 
between 10 to 60 days after immersion.[61] 
Other studies found that glistenings increase with postoperative 
time.[78] One study confirmed the increase in mean glistening density up to the last 
follow-up at 28 months.[84] Tognetto et al. evaluated glistenings in 7 different 
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foldable IOLs, including 2 silicone, 3 hydrophilic acrylic and 2 hydrophobic acrylic 
(AcrySof and Sensar) IOLs. All materials had different degrees of glistenings. In all 
groups, except the AcrySof, the percentage of eyes having glistenings increased up to 
90 days, and then stabilized. The AcrySof IOL group increased continuously up to 
720 days. The mean glistening grade increased in all groups up to 180 days, except 
for the AcrySof and the 911A (silicone) IOLs, which increased continuously.[53]  
 
2.7 GLISTENINGS IN HYDROPHOBIC ACRYLIC LENSES 
 
The currently used hydrophobic acrylic IOLs are manufactured from different 
materials and by different manufacturing processes. The 2 main manufacturing 
methods are mentioned earlier; direct cast molding and sheet casting and lathing. 
Most studies in the literature have investigated glistening in the AcrySof 
material, and only a few studies have given attention to some, but not all, of the other 
hydrophobic acrylic IOLs on the market. Despite the scarce literature on other 
hydrophobic acrylic IOLs, it is likely that various hydrophobic acrylic IOLs exhibit 
different tendencies towards glistening formation. 
An early study of the VA60CB (Acryfold) IOL (Hoya Corp., Japan), 
which is manufactured by lathe-cutting, showed that glistening was found in a much 
higher percentage in the Acryfold IOLs  (62.1%) than in SA30AL (AcrySof) IOLs 
(35.3%). The same study also investigated the Sensar AR40e IOL (Abbott Medical 
Optics), which showed no glistening 6-18 months after implantation.[85] A team in 
Hoya Surgical Optics GmbH implemented improvements in the polymerization and 
cleaning processes. According to Hoya Corp. continued monitoring of the 
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manufacturing processes and customer complaints shows that these changes have 
been effective.[70] The early IOL  
models of VA60CA and VA60CB were discontinued and never released outside 
Japan. 
The XACT IOL is a 3-piece IOL launched in USA by Advanced Vision 
Science (USA), and is available in Japan with the trade name Eternity (Santen, Osaka, 
Japan).  The material was later licensed to Bausch and Lomb, which has launched the 
same material as a 1-piece IOL (enVista). The XACT/enVista IOLs are the only 
hydrophobic acrylic IOLs packaged in solution. Clinical studies included in the FDA 
marketing application for the IOL showed no glistenings between 1 and 6 months in 
these IOL packaged in the currently used 0.9 % saline solution.[86]  
A recent in vitro study reported that continuous manufacturing process 
improvements in AcrySof IOL materials have resulted in a significant reduction in glistening 
density (87% reduction in mean density) in AcrySof IOLs manufactured in 2012 compared to 
AcrySof IOLs manufactured in 2003.[87] 
 
2.8 GLISTENINGS IN SILICONE LENSES 
 
In an in vitro study Miyata et al. evaluated 2 silicone lenses; the SI40NB (Allergan, 
Inc.) and AQ110NV IOLs (Canon Staar). The IOLs were immersed in physiological 
saline at 50°C for 2 hours and then immersed in physiological saline at 35°C for 90 
days. With slit lamp examination a granular opacity in the SI40NB IOLs and slight 
optic opacity in the AQ110NV IOLs were noted. These opacities decreased over time, 
but were still seen in a mild degree up to 90 days. Microvacuoles smaller than 5 μm 
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in diameter were seen when examining the IOLs under a light microscope. The 
opacities disappeared in both IOLs after drying.  
The AcrySof IOL was shown to have a significantly higher mean 
vacuolar density than the silicone CeeOn Edge 911A IOL (Pharmacia) after 3 years in 
a clinical study with 25 patients in each IOL group.[88] 
Two silicone IOLs (CeeOn Edge 911A IOL and SI40NB) were among 
the 7 different IOLs compared in the study by Tognetto et al.[53] Seven days after 
surgery 9% in the CeeOn Edge IOL group had glistenings, and 90 days after surgery 
50% had glistening, with no further increase after that. There was a continuous 
increase in the mean grade of glistenings over time. In the SI40NB IOL group 47% 
had glistenings after 7 days and 50% after 30 days, remaining stable after that. The 
mean grade stabilized after 30 days and was lower than in the CeeOn Edge IOL. 
The silicone iris-fixated phakic IOLs Artiflex have also been shown to 
have glistenings in a clinical study; four out of 20 IOLs were shown to have 
glistenings. The glistenings were not clinically significant and did not increase over 
time.[89] 
In the early 1990s central haze and brown discoloration was observed in 
silicone IOLs. This was suggested to be caused by water vapor, which resulted from 
an anomaly in the curing process or incomplete extraction of large polymers. It was 
considered clinically insignificant. Improvements in the manufacturing process of 
silicone IOLs seemed to remove the discoloration.[90] 
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2.9 GLISTENINGS IN PMMA LENSES 
 
The first observation of lens glistenings was in a PMMA IOL, and was reported in a 
letter by Ballin in 1984.[54] A 4 year prospective study of  73 eyes implanted with a 
PMMA IOL showed glistenings in 89% of the IOLs. No glistenings was observed 
before 3 years, and after 7 years all the IOLs had glistenings. The changes were first 
seen near the anterior and posterior surfaces and then became diffuse throughout the 
entire optic. There was no influence on the visual function.[55] 
Glistenings must be differentiated from “snowflake degeneration” in 
PMMA IOLs. This may occur as long as 10 years after implantation and is a slow, 
progressive opacification of the PMMA IOL. The snowflake degeneration was 
observed in PMMA manufactured by injection molding and implanted in the early 
1980s and mid1990s. It was suggested it resulted from UV exposure. It was found 
spherical lesions in explanted IOLs in the central and midperipheral parts of the optic, 
interpreted as degenerated PMMA material. The peripheral zone of the optic are free 
of “snowflakes”, probably because it is protected by the iris.[91] 
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3 SUBJECTIVE VISUAL FUNCTION 
 
3.1 INTRODUCTION 
 
The goals of cataract surgery are improvement in visual function and quality of life. 
Visual acuity remains one of the most important clinical outcomes after cataract 
surgery for the surgeon. However, the perceived ability to perform everyday task is 
probably the most important outcome for the patient. The use of visual acuity neither 
estimates the full impact of cataract before surgery nor assesses the full benefit for the 
patient after surgery. Hence, visual acuity is a too blunt measure of clinical outcome 
after cataract surgery used alone. Information about how patients experience their 
visual function is important.  
Assessment of patient-reported visual function has in the last decades 
increasingly been used to measure the impact of cataract surgery on visual disability. 
 
3.2 QUESTIONNAIRES AND RASCH ANALYSIS 
 
 Many questionnaires have been developed for the purpose of measuring patient 
reported visual function.[92-96] Most of the questionnaires have been developed 
using classical test theory (CCT), which have several shortcomings.[97] 
CCT has two main problems. Firstly CCT does not provide for interval-
level measurement, and secondly it does not allow insight into the psychometric 
properties of the questionnaire. Likert scoring, used in traditional CCT, uses scores 
that are simple sums of ordinal values, like 1, 2, 3, 4 which are applied to response 
options (no difficulty, some difficulty, great difficulty, very great difficulty), and then 
the sum of these ordinal values is calculated across all questions. This scoring is built 
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on two wrong assumptions.  It assumes that the quantitative difference between each 
response option is equal and that each item/question has the same value. However, 
neither assumption is valid, which make scoring non- linear. 
These problems can be solved with Rasch analysis, which is a mathematical model 
based on probabilistic relationships between items (e.g., questions) and persons (e.g., 
patients).  With the Rasch model the probability of a specified response is modeled as 
a function of person and item parameters. The probability of a response is modeled as 
a logistic function of the difference between the person and item parameter.  The 
Rash model characterizes the ability of the patients and the difficulty of the items as 
locations on a continuous latent variable. Rasch analysis makes interval level 
measurement possible from raw questionnaire data, and therefore parametrical 
statistics can be used on the measurement data. This analysis also provides insights 
into psychometric properties of the questionnaires.  
The advantages of improved psychometric assessment and interval-level 
scoring have led to the development of new questionnaires[98, 99] using Rasch 
analysis and to reengineering of existing questionnaires.[100-104] A study compared 
16 Rasch-scaled cataract surgery questionnaires to find the most responsive to 
cataract surgery (ability to detect clinically important change). The study found that 
all the Rasch-scaled questionnaires tested are psychometrically robust and suitable for 
use, but the Catquest- 9SF[104] was the most responsive. 
 
3.3 VARIABLES  INFLUENCING  SUBJECTIVE VISUAL FUNCTION  
 
All county councils in Sweden agreed in 2003 to let patients select their health 
treatment providers, while allowing the money to follow the patients. Also, a political 
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founded national guarantee for a maximum waiting time for treatment of 3 months 
was implemented on November 2005 in Sweden. [105] These two health policy 
decisions made it more important to evaluate the at the time large variations in 
indications for cataract surgery. To ensure that the entire population in Sweden would 
receive health care on equal terms, an instrument, Nationell Indikationsmodell för 
kataraktextraktion (NIKE) was proposed by Lundström et al. in 2006.[106] The 
purpose was that this instrument should be used as a new clinical tool for establishing 
levels of indications for cataract surgery. A second version of NIKE is now widely 
used in Sweden. 
With this background it became increasingly important to identify and 
assess potential predictors with influence on patient assessed visual function after 
surgery, because this may be helpful when setting indications for surgery. There may 
be many potential predictors influencing the subjective visual function after surgery, 
and it is important to keep this in mind when deciding the levels of indications and 
informing the patients before cataract surgery.  
Many developed countries have waiting lists for cataract surgery, and 
this surgery is usually performed on a first-in, first-out basis. There is not always an 
apparent relationship between time spent on waiting lists and the urgency of cataract 
extraction.[107] Many studies have shown an increased incidence of falling with 
resulting fractures during the waiting time.[108]  
Only a few published studies have tried to identify potential factors 
influencing the duration of waiting time. One study found that the presence of 
anisometropia shortens the waiting time.[109] Other studies have found that women 
wait longer than men,[110]  older patients wait longer than younger patients, and a 
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lower socio-economic status increases the time on the waiting list.[111] Regarding 
the relation between subjective visual function and waiting time, one study showed 
that patients with a short waiting time of 1 month had a lower preoperative subjective 
visual function than patients waiting for surgery for 12 months.[108]  Another study 
found no association between the preoperative Visual Functioning index score and 
the waiting time.[112] 
There is scarce published evidence addressing the relation between 
patient-assessed visual function after cataract surgery and waiting time. One study 
showed that patients reporting general difficulties in daily living spent shorter time 
waiting for surgery, and that the waiting time did not significantly influence changes 
in VF-14 scores.[113] 
Several studies have shown a higher preoperative visual function in men 
than in women,[114-116] indicating that men seek treatment for cataract at a lower 
level of perceived visual disability. One study found a higher subjective visual 
function in men also postoperatively.[116] The same study found no significant 
gender-related differences in CDVA (corrected distance visual acuity) of the operated 
eye before or after surgery. 
One study showed that patients ≥85 years old had on average a good 
result regarding self-assessed visual function as measured by the Catquest 
questionnaire, although not as good as younger patients. Patients in the ≥85 years age 
group had a significantly higher no-benefit outcome than patients in the ≤84 group 
when no ocular comorbidity was present. However, when ocular comorbidity was 
present, there was no significant difference regarding no benefit.[117]   
 30 
 
Earlier studies have had conflicting results regarding how the 
preoperative CDVA in the operated eye influences postoperative subjective visual 
function.  Several studies reported that a low CDVA before surgery increases the 
subjective visual function after surgery.[118, 119] Other studies have shown that 
when adjusting for ocular comorbidity, the preoperative CDVA does not influence the 
level of postoperative subjective visual function.[120, 121] The vision of the better 
eye has been shown to influence the subjective visual function more than the vision of 
the worse eye.[114, 122].  
Many studies have reported higher self-assessed visual function after 
second eye surgery compared to after first eye surgery.[123-125] 
Ocular comorbidity has been shown to reduce subjective visual function 
after cataract surgery. [120, 126, 127]  
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4 GENERAL AIMS 
 
Paper I: To compare PCO with 3 different IOLs 5 years after phacoemulsification 
cataract surgery and to evaluate if the centration of the anterior capsulorhexis 
influences PCO.  
Paper II: To compare PCO and ACO with 3 different IOLs 12 years after 
phacoemulsification cataract surgery. 
Paper III: To compare the amount of intraocular lens glistening in 3 different IOLs 12 
years after surgery. 
Paper IV: To evaluate the influence of preoperative predictive factors on subjective 
visual function after phacoemulsification cataract surgery. 
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5 MATERIAL AND METHODS 
 
5.1 PAPER I - PCO AT 5 YEARS 
 
5.1.1 Study design 
 
This was a prospective randomized study. The study was performed during the 
years 1995-1998, and 180 patients who underwent cataract at St. Erik’s Eye 
Hospital were randomized to implantation with 3 different IOLs: a HSM-PMMA 
IOL (809C, Pharmacia & Upjohn, Uppsala, Sweden) (n=61), a foldable silicone 
IOL (SI-40NB, Allergan, Irvine, CA) (n=60), or a foldable hydrophobic acrylic 
IOL (AcrySof MA60BM, Alcon, Fort Worth, TX) (n=59). The acrylic IOL had a 
sharp posterior edge and the silicone and the HSM-PMMA IOLs had round 
posterior edges. The optical diameter of the HSM-PMMA IOL was 5.0 mm. Both 
the acrylic and silicone IOLs had 6.0 mm optical diameters and loop haptics 
angulated by 10 degrees. The patients were between 60 and 83 years old (mean, 73 
years) at the time of surgery. 
 
5.1.2 Inclusion/exclusion criteria 
 
Patients with corneal pathology, exfoliation syndrome, glaucoma, a history of 
uveitis or intraocular surgery, preoperative oral steroid therapy, and diabetes 
mellitus were excluded. The patients had no other ocular pathology except cataract. 
All the patients had a potential VA of 20/40. Patients with mild macular 
degeneration were included. 
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5.1.3 Surgery 
 
Preoperatively the pupil was dilated and topical and subconjunctival anesthesia 
was administered. One cataract surgeon performed all the operations. A 
corneoscleral incision was made and the ophthalmic viscoelastic device Healon 
(Pharmacia, Uppsala) was used.  Hydrodissection and hydrodelineation was 
performed with balanced saline solution (BSS). Phacoemulsification was 
performed in the capsular bag and irrigation/aspiration with BSS and adrenaline for 
intraocular infusion was used to remove cortical lens material. The incision was 
widened and the IOL was implanted in the bag. Topical dexamethasone was 
prescribed for 3 weeks in a tapered dose after surgery. 
 
5.1.4 Experimental Design 
 
At the 5-year follow-up visit, the corrected distance visual acuity (CDVA) was 
recorded, the pupil was dilated and a retroillumination digital photograph of the 
posterior capsule was taken using a slit lamp and photographic setup to evaluate 
the PCO. The POCOman computer-analysis system was used to analyze the 
images.[46] The POCOman measures the PCO fraction semi-quantitatively and the 
PCO severity qualitatively. In this program PCO fraction is defined as the PCO 
percentage of the total area of the posterior capsule inside the capsulorhexis. The 
POCOman exploits the concept that the human eye is good at recognizing PCO, 
but not at quantifying it. To evaluate the PCO with the POCOman program, the 
IOL optic rim was marked and the capsulorhexis was drawn interactively on the 
loaded image of the posterior capsule. The posterior capsule was divided into 
several small segments by an applied grid. All small segments with an area of PCO 
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exceeding 50% of the segment’s total area were semi quantitatively marked by an 
interactive observer and qualitatively graded as mild, moderate or severe. The PCO 
fraction (in %) and PCO severity were then calculated by the POCO man program. 
One observer performed two measurements and the average was calculated. 
The same retroillumination images were used to evaluate the position 
of the anterior capsulorhexis in relation to the anterior optic. The capsulorhexis 
position was graded as completely centered, i.e. the rhexis was overlapping the 
IOL optic 360 degrees around, partly decentered, or completely off relative to the 
anterior optic. 
Nd:YAG capsulotomy rate before the 5-year follow-up visit was recorded. Patient-
reported complaints and/or a decrease in VA attributable to PCO on the slit-lamp 
examination were criterion for the need to perform Nd: YAG capsulotomy. 
 
5.1.5 Statistical analysis 
 
Kruskal-Wallis analysis of variance with multiple comparisons was used to analyze 
the PCO fraction and severity and the CDVA. The PCO rates at various positions 
of the anterior capsulorhexis was analyzed with the Mann-Whitney U test. The chi-
square test was used to compare the Nd: YAG capsulotomy rates between the 
groups.  
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5.2 PAPER II -PCO AT 12 YEARS 
 
5.2.1 Study design 
 
Prospective randomized study with 12 years of follow-up. The study was en extended 
follow-up of the study in paper I, the design was the same as described for paper I. 
 
5.2.2 Inclusion/exclusion criteria 
 
The inclusion/exclusion criteria were the same as in paper I. 
 
5.2.3 Surgery 
 
The surgery was performed as described for paper I. 
 
5.2.4 Experimental design 
 
Retroillumination digital photographs of the posterior capsule was taken and the 
POCOman computer-analysis system was used to analyze the images and calculate 
the PCO fraction and severity in a similar fashion as described in paper I. 
 Slit lamp digital photographs of the anterior capsule were taken to evaluate 
the ACO. ACO was graded subjectively both directly at the slit lamp and by 
evaluating the anterior capsule photographs. We combined one image taken at the 
nasal side and on image taken on the temporal side to produce one image of the 
entire anterior capsule. A subjective grading system previously described was used 
to grade the ACO. [128] We evaluated two subtypes of ACO: the ACO at the 
capsulorhexis edge and ACO of the entire anterior capsule that was in contact with 
the optic, i.e. diffuse ACO.  Each subtype was divided into four severity grades: 
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none (clear/transparent anterior capsule), mild (mild whitening without capsular 
folding), moderate (moderate whitening, sometimes with areas of capsular 
folding), and severe (intense whitening, with areas of capsular folding).  
The number and timing of Nd: YAG capsulotomies during the 12 year 
period from surgery to the end of the study were recorded. The median time and the 
overall survival without Nd: YAG capsulotomy were calculated. The median survival 
time is when 50% of the patients had undergone Nd: YAG capsulotomy. The overall 
survival was calculated using Kaplan Meier survival analysis, and the whole period 
from surgery to 12 years after surgery was taken into account. i.e. the survival is not 
calculated for the 12 year time end point, but for the whole period. Kaplan Meier 
survival analysis offers advantages in long time studies with many patients lost to 
follow-up, because it makes use of the information from these patients up to the date 
of last examination before they are lost to follow-up. 
 
5.2.5 Statistical analysis 
 
Kruskal-Wallis analysis of variance with multiple comparisons was used to analyze 
ACO and PCO fraction and severity. The survival rate without Nd:YAG capsulotomy 
was calculated with survival analysis with  Cox regression. The Wilcoxon-Gehan 
exact test with pairwise comparisons was used to analyze the overall survival between 
the groups. Kaplan-Meier curves was used to illustrate the survival time without 
Nd:YAG capsulotomy for the three IOLs and for men and women. 
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5.3 PAPER III- LENS GLISTENINGS 
 
5.3.1 Study design 
 
Prospective randomized study with 12 years of follow-up, an extended follow-up of 
the study described in paper I. The study design was the same as described for paper I 
and II. 
 
5.3.2 Inclusion/exclusion criteria 
 
The inclusion/exclusion criteria were the same as in paper I and II. 
 
5.3.3 Surgery 
 
The surgery was performed as described for paper I. 
 
5.3.4 Experimental design 
 
Each eye was photographed with the Pentacam® HR Scheimpflug camera (Oculus 
Inc., Lynnwood, WA, USA). This noninvasive system uses the principle of 
Scheimpflug imaging to characterize the anterior ocular segment. Lens and image 
planes of a camera are normally parallel, and the plane of focus is parallel to the lens 
and image planes. If the subject is not parallel to the image plane only a small area is 
in focus with a normal camera. The main difference between the Scheimpflug 
imaging and conventional techniques is that the object plane, lens plane, and image 
plane are not parallel to each other, but intersect in a common straight line. The main 
advantage of the Scheimpflug technique is that it yields a wide depth of focus. This 
method to measure light scattering and glistening has been described previously.[64, 
66, 67] The objectivity is higher with Scheimpflug imaging than subjective staging of 
glistenings at the slit lamp. This technique also provides information about the axial 
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location of the glistenings. Objective grading of glistenings with the Scheimpflug 
technique has been shown to correlate well with clinical grading.[129] 
We used a superior and a temporal camera position when taking the 
Scheimpflug images. The ImageJ image analysis program was subsequently used to 
analyze the images. This program can be used to quantify the degree of light 
scattering within the full or part thickness of the IOL from the Scheimpflug images in 
a 1.5-mm zone at the visual axis. The light-scattering data was further processed in a 
macro written in Microsoft Excel. The peak light scattering sometimes seen on the 
posterior IOL, was interpreted as PCO and was therefore discarded by the macro. The 
degree of light scattering/glistenings was expressed in arbitrary units (AU). 
The IOL optic is approximately 500 μm thick. The glistening was evaluated in the 
entire thickness, in the deep interior (the middle 350 μm) and the very deep interior 
(the middle 300 μm) of the IOL optic.  
 
5.3.5 Statistical analysis 
 
The lens glistenings among the three IOLs were compared using The Kruskal–Wallis 
analysis of variance with multiple comparisons. Regression analysis could be used to 
analyze the influence of IOL power on lens glistenings only in the hydrophobic 
acrylic group, because too small amount of glistenings appeared in the other groups. 
 
5.4 PAPER IV - SUBJECTIVE VISUAL FUNCION 
 
5.4.1 Study design 
 
This prospective multicenter study included 14 817 patients with cataract who 
underwent surgery from 2000 to 2006. The data was extracted from the Swedish 
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National Cataract Register (NCR). Forty-two ophthalmology surgical units in Sweden 
participated in the study. During the month of March of each year during the study 
period the Catquest questionnaire was used for all patients who had undergone 
cataract surgery in the participating surgical units. The patients completed the 
Catquest questionnaire before and 6 months after surgery. The Catquest 
questionnaire, which is based on CTT and Likert scoring, was originally used by the 
Swedish NCR from 1995 for collecting data on subjective visual function after 
cataract surgery. This questionnaire comprises 17 items. The Rasch-scaled Catquest-
9SF questionnaire was developed after assessing and optimizing the Catquest 
questionnaire using Rasch analysis. The resulting 9 questions in the revised Catquest-
9SF were extracted from the Catquest for analysis. The Catquest-9SF questionnaire 
contains 7 questions about perceived difficulty in performing specific activities 
during daily life and 2 global questions about general difficulties in performing 
activities in daily life and about general satisfaction with vision. There are 4 response 
options to each question, which designates different levels of visual function. 
In this study the relations between 10 different predictive factors and 3 response 
variables were assessed. The nonparametric grading of answers was re-coded by 
Rasch analysis, making it possible to perform parametric statistical analysis.[104] The 
first response variable was change in patient-reported visual function from before to 6 
months after surgery. The other 2 response variables were both from 6 months after 
surgery. The second response variable was the average outcome of all the questions in 
the questionnaire 6 months after surgery, hereafter referred to as mean visual 
outcome. The third response variable was the question about general satisfaction with 
vision in the questionnaire 6 months after surgery. The question regarding general 
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satisfaction also had 4 response options, but in the analyzing process this variable was 
dichotomized into generally satisfied or generally dissatisfied. 
The covariates analyzed in relation to the response variables were  
-waiting time before surgery (months) 
-gender 
-patient age (years) 
-corrected distance VA (CDVA) logarithm of the minimum angle of resolution 
(logMAR) before and after surgery 
-a first- or second-eye cataract surgery 
-ocular comorbidity (yes/no) 
-achieved postoperative refraction (diopters [D]) 
-correct sign biometry prediction error (D) 
- absolute biometry prediction error (D) 
 
The CDVA was first measured in Snellen decimal VA and then converted to 
logMAR. Macular degeneration, glaucoma, diabetic retinopathy or other ocular 
diseases were the ocular comorbidities reported in the NCR.  The achieved 
refraction was calculated as the spherical equivalent of the spherical and astigmatic 
corrections at the final follow-up.  The spherical equivalent was categorized into 4 
different levels: High myopia (<−2.0 D), myopia (−2 to 0 D), hyperopia (>0 to +2 
D), and high hyperopia (>+2 D). 
The correct sign biometry prediction error (refractive surprise) was the 
difference between targeted and actually received refraction, and was calculated in 
spherical equivalents. This covariate was also categorized into 4 levels: 
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Unexpectedly high minus (<−2 D), unexpected minus (−2 to 0 D), unexpected plus 
(>0 to +2 D), or unexpectedly high plus (>+2 D). 
 
5.4.2 Statistical analysis 
 
Parametric statistics could be used, because the questionnaire raw data was recoded 
using Rasch analysis. The logit unit, which is the natural log-odds of a participant 
being successful versus being unsuccessful at a task,[102] was used for the response 
variables change in subjective visual function and the mean subjective visual 
function. 
In all analysis multivariate statistics were used. Multiple regression was 
used for the continuous response variables change in subjective visual function and 
mean visual outcome, with dummy variables when appropriate. The third response 
variable, the global question about satisfaction with vision, was dichotomized and 
logistic regression was used. For all statistical analysis we used STATA/IC 10.1 
(Stata Corp., College Station, TX). 
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6  RESULTS AND DISCUSSION  
 
6.1 PAPER I AND II – PCO AT 5 AND 12 YEARS 
 
6.1.1 Patient data at 5 years 
 
At the 5 year follow-up, 28 of the initial 180 patients were lost to follow-up. The 
statistical analysis included 152 patients. 
 
6.1.2 CDVA and PCO at 5 years 
 
There was no significant difference in CDVA in the 3 IOLs. The previously Nd: 
YAG treated patients were excluded in the analysis of CDVA.  
The POCOman PCO calculations were performed both when the patients who had 
previously undergone an Nd: YAG capsulotomy were included, and when they were 
excluded. The patients that had undergone Nd: YAG capsulotomy before the 5 year 
control were given the highest rank in the statistical analysis of PCO and excluded 
from further image analysis.  
In the calculation of POCOman PCO scores including the Nd: YAG 
treated patients the HSM-PMMA IOL group had a significantly higher fraction (%) of 
PCO than the silicone (P = 0.00003) and the acrylic (P = 0.000001) IOL groups, but 
there was no significant difference between the silicone and the acrylic (P = 1.0) IOL 
groups. The HSM-PMMA IOL group also had significantly higher PCO severity than 
the silicone (P = 0.000082) and acrylic (P = 0.000001) IOL groups, but there was no 
significant difference between the silicone and the acrylic (P = 1.0) IOL groups. 
When the Nd: YAG treated patients were excluded in the calculation, the same 
relationships in PCO fraction and PCO severity between the three IOL groups were 
also true (but with slightly different P values). 
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6.1.3 Nd: YAG capsulotomy rates at 5 years 
 
At the 5 year control the HSM-PMMA IOL group had a significantly higher Nd:YAG 
rate than the than the silicone (P = 0.012) and acrylic (P<0.0001) IOL groups. The 
silicone group had a significantly (P = 0.0068) higher Nd:YAG rate than the acrylic 
group up to 5 years (Table 1). After the 5 year control (when the eyes evaluated to 
need Nd:YAG capsulotomy at the 5 year control were included) the Nd:YAG 
frequency in the HSM-PMMA IOL group still was significantly higher than in the 
silicone (p = 0.0051) and AcrySof (p = 0.0001) groups. However, it was no 
significant difference in Nd:YAG capsulotomy rate between the silicone and AcrySof 
(p = 0.21) IOL groups after the 5 year control. The Nd: YAG rates before and after 
the 5 year control are listed in table 1. 
Table 1. Nd:YAG frequency before and after the 5-year follow-up. 
Parameter  
HSM 
PMMA 
809C  
Silicone      
SI-40NB  
AcrySof 
MA60BM  
n= 54 n= 48 n= 50 
Nd:YAG 
frequency(%) 
at the 5-year 
follow-up 
54 29 8 
Nd:YAG 
frequency(%) 
after the 5-
year follow-
up 
61 33 22 
 
6.1.4 Anterior capsulorhexis at 5 years 
 
We found an anterior capsulorhexis with complete centration on the anterior optic 
360 degrees around in 90 patients, and a partly decentred capsulorhexis in 53 patients. 
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In 4 patients the capsulorhexis was completely off the optic, and this group was 
excluded from the analysis since they were so few. Taking into account all the 
patients in the study, the PCO fraction (p= 0.0076) and severity (p=  
0.0081) were significantly higher when the anterior capsulorhexis was partly off the 
IOL optic than when it was completely in contact with the IOL optic.  
This was not true when comparing separately in each of the 3 IOL 
groups. There was no significant difference between eyes with centered and partly 
decentered capsulorhexis within each of the 3 IOL groups. 
 
6.1.5 Patient data at 12 years 
 
After the mean follow up time of 12.3 years (11.3 to 13.4 years) 74 patients were lost 
to follow-up and 106 patients were eligible for further analysis. The patients we knew 
had undergone Nd: YAG capsulotomy were not asked to come to the 12 year 
examination. 46 patients came to the 12 year follow-up and were photographed. The 
photographs were evaluated for ACO in 46 patients and for PCO in 36 patients. Nine 
patients who came to the 12 year follow-up had already had a  
Nd: YAG capsulotomy elsewhere and 1 patient was excluded from the PCO analysis 
because of poor image quality. 
 
6.1.6 PCO at 12 years 
 
 The HSM-PMMA IOL had significantly higher PCO fraction than the silicone IOL 
(P < 0.05), but between the HSM-PMMA and acrylic IOLs (P = 0.45) or the silicone 
and acrylic IOLs (P = 1.0) there was no significant difference.  
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There was no significant difference regarding PCO severity between the HSM-PPMA 
and silicone (P = 0.052), the HSM-PMMA and acrylic IOLs (P = 0.47) or the silicone 
and acrylic IOLs (P = 1.0). 
 
6.1.7 Survival without Nd: YAG capsulotomy during 12 years 
 
One-hundred-and- seventy-nine patients were included in the statistical analysis of 
the median and overall Nd: YAG free survival time. One patient in the silicone group 
was excluded because of intraoperative capsule rupture. 
 The median survival time without Nd:YAG capsulotomy was 53 months in the 
PMMA, exceeded 150 months in the silicone, and was 108 months in the acrylic IOL 
group. The acrylic IOL had a significantly higher overall survival without Nd: YAG 
than the PMMA IOL (P < 0.001). There was no significant difference in overall 
survival between the PMMA and silicone (P=0.073) or the acrylic and silicone (P = 
0.17). Because the median time of Nd:YAG-free survival was highest in the silicone 
group, this result may seem contradictory. However, in the calculation of the overall 
survival the whole survival curve from surgery to 12.3 years after surgery is taken 
into consideration. Events in the start of the curve, when more patients were at risk, 
were more important than later. 
The median survival time without an Nd:YAG capsulotomy in men exceeded 
150 months and was 63 months in women. There was no significant difference in overall 
survival (P =0.173) between men and women. 
 
6.1.8 ACO at 12 years 
 
The silicone IOL had significantly more edge ACO than the acrylic IOL evaluated in 
photographs.  (P = 0.041), but there was no significant difference between the 
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silicone and the PMMA IOLs (P = 1.0) and the acryl and the PMMA IOLs (P = 
0.067). 
Edge ACO evaluated clinically at the slit lamp (P =0.136), diffuse ACO 
evaluated at the slit lamp (P =0.246) or in photos (P = 0.479) did not differ 
significantly between the three lenses. 
 
6.1.9 Discussion paper I and II - PCO at 5 and 12 years 
 
It is important to inhibit PCO development in a long period after surgery, since many 
patients will live more than 10 years after phacoemulsification surgery. 
The results from our studies indicate that even though a sharp-edged hydrophobic 
acrylic IOL may delay PCO development in the early years after surgery, the PCO 
protective effect of this IOL seems at the best, very low, at 5 years and almost lost at 
12 years compared to a round-edged silicone IOL. Both the silicone IOL and the 
acrylic IOL could prevent PCO in comparison with the PMMA IOL after 5 years, but 
after 12 years this advantage was reduced or lost. 
After 12 years all the three IOLs tended to induce about the same 
amount of PCO, even though the PMMA IOL still had a higher PCO fraction than the 
silicone IOL after 12 years. In the Kaplan Meier survival analysis there was a better 
overall Nd: YAG free survival in the acrylic IOL than in the PMMA IOL, i.e. when 
taking the whole period from surgery to 12 years after surgery for all the patients into 
consideration. Between the sharp-edged acrylic and the round edged silicone there 
was no difference in overall survival over the 12 years after surgery, even though the 
survival curve indicates that the acrylic IOL tend to inhibit PCO better in the early 
years and is surpassed by the round-edged silicone lens after about 6.5 years, which 
thereafter has a better Nd: YAG free survival. 
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There are not many studied in the literature with duration of 5 years or 
more, and many studies with shorter duration is complicated by the fact that they 
compare round edge IOLs with sharp edge IOLs.  Two earlier studies indicate that a 
silicone IOL protects better against PCO than a hydrophobic acrylic IOL after 6 and 
10 years.[51, 52] Another study showed that 10 years after surgery the Nd:YAG 
capsulotomy rates with silicone and hydrophobic acrylic IOLs were lower than those 
with PMMA IOLs, and there was no significant differences in Nd:YAG rates between 
a sharp-edged acrylic IOL and a round-edged silicone IOL.[82]  
The reason behind why the acrylic IOL seems to lose the advantage 
regarding PCO inhibition it had in the earlier years after surgery, is probably loss of 
the barrier effect of the sharp edge. This delayed barrier failure is a result of late 
proliferation of LECs and creation of an emerging Soemmering ring in the peripheral 
capsular bag. The mechanical pressure from the Soemmering ring break the seal 
between the fused anterior and posterior capsule leaves. The barrier effect of the 
sharp edge is thereby lost and the LECs are free to migrate into the posterior capsule 
behind the optic.  
The silicone IOL seems to offer effective protection against PCO in the 
long time run. This may reflect a specific material property. The silicone material is 
thought to have a higher adhesiveness to collagen and vitronectine and also to 
catalyze transdifferation of LECs into myofibroblasts, which lays down collagen. 
This creates a strong sealing `glue` at the sharp edge between the anterior and 
posterior capsule, which probably can withstand the mechanical pressure from the 
proliferating LECs for a longer time. 
Previous clinical and autopsy studies have reported more ACO with 
silicone IOLs than with acrylic IOLs.[15, 130, 131] A high degree of ACO in silicone 
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lenses may create a greater backward pressure, which mechanically hinder LECS to 
migrate. 
In conclusion, 5 to 12 years after surgery a sharp-edged acrylic IOL 
could not prevent PCO in comparison to a round-edged silicone IOL. According to 
the Nd:YAG free survival curve the acrylic IOL seemed to protect against PCO the 
best in the early years, but was surpassed by the silicone IOL after about 6.5 years. 
The total PCO protection benefit during the entire 12 year period, as reflected by the 
overall survival, seemed to be the same for both the acrylic and the silicone IOLs. 
 
6.2 PAPER III – LENS GLISTENINGS 
 
6.2.1 Patient data 
 
Forty-six patients were available for evaluation of lens glistenings after a median 
follow-up time of 12.2 years (11.3 to 13.4 years). Eleven of the eyes were in the 
PMMA IOL group, 16 eyes were in the silicone IOL group and 19 eyes were in the 
hydrophobic acrylic IOL group.  
 
6.2.2 Lens glistenings 
 
All 3 IOL groups had glistenings. Considering the entire thickness of the optic, the 
median amounts of lens glistenings were 0 AU (range, 0–15.9) in the PMMA IOL, 
256.1 AU (range, 0–967.7) in the silicone IOL and 662.0 AU (range, 74.6–1591.1) in 
the hydrophobic acrylic IOL. There was significantly more lens glistenings in the 
hydrophobic acrylic IOL than in the silicone (p = 0.003) and the PMMA (p = 0.000) 
IOLs. This relation was also true for the deep and the very deep interior glistenings, 
but with different p-values. The silicone IOL had significantly more lens glistenings 
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than the PMMA lens (p = 0.048) regarding glistenings in the entire thickness of the 
optic. There was no significant difference between the silicone and the PMMA IOLs 
considering the deep (P = 0.08) and the very deep glistenings (P = 0.10). 
 
6.2.3 Influence of IOL dioptric power on lens glistenings 
 
The degree of lens glistenings in the hydrophobic acrylic IOL group was not 
influenced by the IOL dioptric power (P = 0.64). Statistical analysis could not be 
performed in the other 2 IOL groups, because the degree of glistenings was too low. 
 
6.2.4 Discussion paper III – lens glistenings 
 
In this 12 year prospective study, the degree of lens glistenings was found to be 
significantly higher in the hydrophobic acrylic IOL than in the silicone and HSM-
PMMA IOLs. The silicone IOL had very little glistenings, but it had significantly 
more than the PMMA, which had almost no glistenings.   
Previously there has been very little research on glistenings in the 
silicone and PMMA IOLs, and to my knowledge no studies with such a long follow-
up time as in our study.  This study shows that even after a very long follow-up time 
of 12 years, these 2 IOLs still do not develop a substantial amount of glistenings.  
One study found no glistenings after 3 years in a PMMA IOL, but 7 years after 
surgery all the PMMA IOLs had some degree of glistenings.[55] Our result is not in 
concordance with this, showing almost no glistenings in the PMMA IOL after 12 
years. 
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One study compared glistenings in 7 different IOLs, and included both 
the same silicone IOL as in our study as well as an AcrySof IOL. The AcrySof IOL 
was shown to have significantly more glistenings than the other IOLs both after 180 
days, 360 days and at the last follow-up 2 years after surgery. The mean grade of 
glistenings in the SI-40NB IOL increased up to 180 days postoperatively and 
remained stable thereafter, and the percentage of SI-40NB IOLs with glistenings 
increased up to 90 days and then stabilized.[53] 
The degree of glistenings in the silicone and PMMA IOLs in our study 
were too low to evaluate if the IOL dioptric power could have an impact on the 
glistenings in these 2 IOLs. 
In the hydrophobic acrylic IOL there was a normal distribution of the 
degree of glistenings, and we found no impact of dioptric power on lens glistenings in 
this IOL. One study agreed and showed that the IOL power does correlate with the 
amount of glistenings[129]. Some other studies, with larger study population than in 
our study, found an association between IOL dioptric power and lens glistenings.[73, 
74, 78] Our findings may be because of the small study group. 
In conclusion, our study shows that even if the degree of glistenings in 
the AcrySof IOL is higher than in the silicone and PMMA IOLs, there is some 
glistenings even in the silicone IOL. The PMMA IOL has almost no glistenings after 
12 years. The dioptric power did not influence lens glistenings in the hydrophobic 
acrylic AcrySof IOL after 12 years.  
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6.3 PAPER IV– SUBJECTIVE VISUAL FUNCTION   
 
6.3.1 Patient -and demographic data 
 
The study included 14817 patients. In 522 patients the targeted refraction was not 
recorded, and these patients were therefore excluded from the study. Nine patients 
completed only the preoperative questionnaire, and 15 patients completed only the 
postoperative questionnaire. It is not possible to calculate the change in subjective 
visual function in these patients, and they were therefore excluded from further 
analysis. When not all of the 9 questions were answered, the mean of the remaining 
questions were used. In total 14271 patients were included in the statistical analysis. 
The final number analyzed for the response variables change in visual function and 
mean visual outcome was 14151, because not all parameters were registered correctly 
in the NCR. Regarding the response variable satisfaction with vision, 13408 patients 
were included, because all the patients did not answer this global question. 
The mean patient age was 75.9 years. There were 64.7% women and 
35.3% men. The percentage of patients with ocular comorbidity was 31.1%. First eye 
surgery was performed in 60.8% and 39.2% had second eye surgery.  
 
6.4.2 Waiting time  
 
A shorter waiting time for surgery led to a higher change in subjective visual function 
from before to 6 months after surgery (P= 0.003), but it had no significant association 
with the 2 postoperative variables. The waiting time for surgery did not significantly 
influence the mean subjective visual outcome postoperatively (P= 0.53) and was not 
significantly associated with the OR of being generally satisfied (OR, 1.0; P = 0.52). 
This indicates that the patients with a shorter waiting time had lower perceived visual 
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function before surgery, but after surgery the waiting time did not influence their 
subjective visual function. The less content patients may have exerted extra pressure 
on the surgeon to have a prompt operation. 
One study was in concordance with our result, and showed that a lower 
preoperative visual function was associated with a shorter waiting time (1 month 
compared to 12 months) waiting time.[108] Another study found that the waiting time 
did not significantly influence the preoperative patient-reported visual function.[112] 
There are few studies exploring the association between waiting time for surgery and 
postoperative subjective visual function. One study showed that waiting time did not 
significantly influence changes in Visual Functioning index score.[113] 
 
6.4.3 Gender 
  
Men had significantly higher mean visual function (P< 0.001) and OR of general 
satisfaction (OR, 1.27; P< 0.001) after surgery compared with women. However, 
women had significantly higher change in subjective visual function from before to 
after surgery compared to men (P 0.001). The reason for this is probably that women 
had a lower subjective visual function than men before surgery. The higher 
improvement in self-reported visual function from before to after surgery for women 
was not enough to make women more content than men postoperatively. Other 
studies also agree with our result regarding higher subjective visual function in men 
before surgery.[114-116] One of these studies also agreed with our result in that men 
had higher subjective visual function than women both before and after surgery.[116] 
It is well-known that gender-related differences have been observed in 
objective and self-reported perceived health in general health care. Women have in 
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previous research been found to have a higher selective attention to their bodies.[132] 
The differences in health-related behavior between men and women have been 
explained with various models. Gender differences in biological makeup in terms of 
genes, hormones and physiology have been emphasized by some, and others have 
focused on life circumstances such as work, family and other socially determined 
factors that may increase the health risk.[133]  
In the response variable change in subjective visual function in our 
study the patient was his or her own control, eliminating the effect of some category 
of patients, for example women or men, being more prone to be discontent with 
health. 
 
6.4.4 Age  
 
Younger patients had a significantly higher change in subjective visual function from 
before to after surgery (P< 0.001) and a significantly higher mean subjective visual 
function after surgery (P< 0.001) compared to older patients. Age was not associated 
with the OR of being generally satisfied (OR, 1.0, P = 0.88). This indicates that 
younger patients both have a higher improvement and a better subjective visual 
function after cataract surgery. One study using the Catquest questionnaire, found that 
patients ≥85 years old had not as good self-reported visual function as patients ≤84 
years old, even though they on average had a good result.[117] 
 
6.4.5 CDVA before and after surgery  
 
A low CDVA before and a high CDVA after surgery were significantly associated 
with a higher change in subjective visual function (P<0.001) and higher postoperative 
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mean subjective visual function (P<0.001) and satisfaction with vision (OR preop 
CDVA, 1.13, P<0.001; OR postop CDVA, 0.37, P< 0.001). This indicates that 
patients with a low preoperative CDVA and a high postoperative CDVA in the 
operated eye both have a higher gain and higher postoperative content with vision. 
Regarding the preoperative CDVA other studies had varying results. 
Some studies reported similar results as ours.[118, 119] Others reported that when 
adjusting for ocular comorbidities, the preoperative CDVA in the operated eye was 
not significantly associated with subjective visual function.[120, 121] Many studies 
agreed with our result regarding the postoperative CDVA.[118, 119, 134, 135] One 
study showed no correlation between postoperative CDVA and satisfaction with 
vision, which did not agree with our result.[135] 
 
6.4.6 First- or second-eye cataract surgery  
 
The 2 postoperative response variables mean subjective visual function (P<0 0.001) 
and satisfaction with vision (OR, 1.99, P<  0.001) were significantly higher in second 
eye surgery patients than in first eye surgery patients. However, first eye surgery 
patients had significantly higher change in subjective visual function from before to 
after surgery (P= 0.001). The explanation for this may be that the first eye surgery 
patients were more dissatisfied before surgery because they may have had bad vision 
in both eyes compared to second eye surgery patients who may have had good vision 
in the already operated eye. This is in agreement with other studies, which have 
shown that the self-reported visual function correlates best with the better eye.[96] In 
most cases the better eye was the eye which already had undergone cataract surgery. 
The second eye surgery patients probably had better self-assessed visual function 
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after surgery, because of good vision in both eyes after cataract surgery with better 
binocular vision and a lower degree of anisometropia as compared with first eye 
surgery patients after surgery. Many studies have had findings in agreement with our 
postoperative result regarding higher subjective visual function after cataract surgery 
in both eyes as compared to after surgery in only one eye.[123-125] 
 
6.4.7 Ocular comorbidity  
 
Absence of ocular comorbidity was associated with a higher change in subjective 
visual function (P<0.001), higher postoperative mean visual function (P<0.001) and 
satisfaction with vision (P<0.001) compared to when ocular comorbidity was present. 
Many studies, using Likert scoring, agreed with this.[114, 120, 126, 127] 
 
6.4.8 Refractive parameters after surgery  
 
Patients with achieved postoperative myopia (−2 to 0 D) had a significantly higher 
change in subjective visual function (P= 0.001) and a significantly higher 
postoperative mean subjective visual function (P= 0.012) compared to patients with 
achieved hyperopia (>0 to +2 D). In the comparisons of any other categories of this 
parameter, there were no significant differences in this 2 response variables of self- 
assessed visual function. Regarding satisfaction with vision the categories of achieved 
postoperative refraction did not differ from each other, with varying P values. 
The reason patients with myopia (−2 to 0 D) had higher subjective 
visual function, may be that with myopia the patients may be independent of 
spectacles for near distance reading, whereas with hyperopia the patients need 
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correction for both near and distance vision. The explanation for the lack of 
significant differences between the other categories may be that there were large 
differences in group sizes.  
We were surprised to find a higher change in the subjective visual 
function in patients with a correct sign biometry prediction error (refractive surprise) 
of unexpected plus (>0 to +2 D) compared to unexpected minus (−2 to 0 D) (P= 
0.006). The categories of correct sign biometry prediction error did not have various 
effects on the postoperative subjective visual function or the odds of being generally 
satisfied, with varying P values. The actual mean spherical equivalents of the patients 
in the groups were −2.8, −0.63, +0.37, and +2.1 D, respectively. Some of the group 
sizes where very small (only 3 % in the (<−2 D) category and 0.8 % in the (>+2 D) 
group), which may explain the lack of significant differences. Also, in the categories 
with larger group sizes, the actual mean spherical equivalents of -0.63 in the group 
with unexpected minus (−2 to 0 D) and + 0.37 in the group with unexpected plus (>0 
to +2 D) where very good refractive results and did not differ much from 0 D, which 
also may be a reason for the lack of significant differences between the categories. 
It was also surprising to find that the absolute biometry prediction error 
did not have any significant association with the change variable (P= 0.70), the 
postoperative mean visual function (P= 0.70) or the satisfaction with vision variable 
(OR, 0.94; P = 0.19). Other questionnaires, like the Quality of Life Impact of 
Refractive Correction questionnaire, may be better at finding significant associations 
between subjective visual function and refractive result after surgery. 
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7 MAIN CONCLUSIONS 
 
1. There was no difference in the evaluation of PCO between the sharp-edged 
hydrophobic IOL and the round-edged IOL 5 years after cataract surgery. The 
HSM-PMMA IOL had more PCO than the other 2 IOLs. The AcrySof IOL had 
lower Nd:YAG rate than the other two IOLs at the 5-year follow-up. 
2. The sharp-edged hydrophobic acrylic and the round-edged silicone IOLs had 
similar PCO semiquantitive evaluation 12 years after surgery. The acrylic IOL 
had significantly better overall survival without Nd: YAG capsulotomy than the 
HSM-PMMA IOL, but between the silicone IOL and the 2 other IOLs there were 
no significant differences. The silicone IOL had the longest median Nd: YAG free 
survival time.  
3. The hydrophobic acrylic IOL had significantly more lens glistenings than the 
silicone and the HSM-PMMA IOL 12 years after surgery. The HSM-PMMA IOL 
had almost no glistenings. The IOL dioptric power did not significantly influence 
the degree of lens glistenings in the hydrophobic acrylic IOL. 
4. A higher change in subjective visual function from before to after surgery was 
significantly associated with a low preoperative CDVA, no ocular comorbidity, 
high postoperative CDVA, first-eye surgery, female gender, young age, 
postoperative myopia, and a correct sign biometry prediction error of plus in 
comparison with their counterparts. A higher postoperative subjective visual 
function was significantly associated with a low preoperative CDVA, no ocular 
comorbidity, a high postoperative CDVA, a second-eye surgery, male gender, 
young age, and postoperative myopia in comparison with their counterparts.  A 
higher OR of being generally satisfied than dissatisfied was significantly 
associated with male gender, no ocular comorbidity, second-eye surgery, a low 
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preoperative CDVA, and a high postoperative CDVA in comparison with their 
counterparts. The subjective visual function after surgery was not significantly 
associated with the absolute biometry prediction error. 
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8 FUTURE PERSPECTIVES 
 
 
We have been able to delay PCO with modern surgical techniques and sharp-edged 
IOLs, but not to eradicate it. A sharp-edged design has been shown to reduce PCO 
during the early years, while lens material may play a role in the long term. The 
prevention of PCO is unfortunately still the largest unmet need in modern cataract 
surgery. The struggle to inhibit PCO is difficult and a fight against nature, because 
LEC migration and transdifferentiation are nature’s back-up strategies to the loss of 
lens tissue. 
In the prevention of PCO there are other features related to capsule 
morphology after IOL insertion that likely play a role. Studies in eyes implanted with 
disc-shaped or dual-optic IOLs have shown that an open and expanded capsular bag 
retains transparency.[136-138] This may be due to the concept “no space - no cells” 
as well as other mechanisms. With no place, there will be no space to grow for the 
LECs. Also, the inner part of the capsular bag may be constantly irrigated by aqueous 
humor when the bag is left expanded and open. A capsular bag exposed to stretch or 
mechanical pressure may result in inhibition of LEC metaplasia, migration and 
proliferation. Such IOL designs may result in better PCO prevention in the future. 
Furthermore, these IOLs may, by restricting fibrosis, offer a more flexible capsular 
bag for an accommodating IOL. 
Other research directions have been applied in clinical practice for many 
years now. Marie-José Tassignon, MD, from Belgium has used the “bag in the lens” 
IOL design and implantation technique. With this technique a specially designed lens 
permits the positioning of both the anterior and posterior capsulorhexis inside a fine 
groove surrounding the optic of the lens.[139] Others have developed a technique of 
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posterior capsulorhexis with posterior optic buttonholing. A 4.5-mm posterior 
capsulorhexis is made and a three-piece IOL is pushed behind it (buttonholing), 
leaving the haptics inside the bag.[140] According to the researches these alternative 
techniques should prevent LECs from gaining access to the retrolental space.  
In the future it would also be interesting to investigate if  cataract 
surgery with femtosecond laser will reduce PCO.  The femtosecond lasers may 
produce a more predictable diameter and centration of the capsulorhexis, and future 
studies may show if this reduces PCO. 
The manufacturers of IOLs are working hard to improve the 
manufacturing process of IOLs to reduce the amount of glistenings. A good example 
of this is that the AcrySof IOL, which has received most of the attention regarding 
lens glistenings, recently has been shown to develop much less glistenings after 
improvements of the manufacturing processes.[87] This offers hope for future 
reduction in the degree of lens glistenings. 
The new Rasch revised questionnaires, evaluating the relation between 
cataract surgery and subjective visual function, offer promise for the future as they 
will produce more reliable results than the old questionnaires based on CTT with 
Likert scoring. Rasch revised questionnaires could also be used to evaluate the 
association between PCO and subjective visual function.[141] It is still controversial 
weather lens glistenings influence visual function. Maybe well-designed studies 
investigating the potential association between patient-reported visual function and 
lens glistenings could contribute to this debate? 
Furthermore, it could be interesting to  investigate how the choice of 
IOL influence the subjective visual function in relation to cataract surgery; and 
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whether for instance any of the new premium IOLs (multifocal, toric, 
accommodating) influence subjective visual function. May performing micro incision 
cataract surgery (MICS) or femtosecond laser cataract surgery influence subjective 
visual function?  
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